Merck & Co Inc.

26 ago 2026, 23:11 UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 ago 2026, 23:06 UTC

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

24 ago 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

21 ago 2026, 19:31 UTC

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

20 ago 2026, 19:31 UTC

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

19 ago 2026, 23:41 UTC

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

17 ago 2026, 19:36 UTC

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

15 ago 2026, 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

14 ago 2026, 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

13 ago 2026, 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

12 ago 2026, 19:56 UTC

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

11 ago 2026, 19:36 UTC

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

10 ago 2026, 19:36 UTC

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7 ago 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6 ago 2026, 23:01 UTC

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5 ago 2026, 19:43 UTC

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4 ago 2026, 23:26 UTC

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3 ago 2026, 20:03 UTC

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 jul 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30 jul 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29 jul 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28 jul 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27 jul 2026, 20:06 UTC

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24 jul 2026, 18:56 UTC

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22 jul 2026, 19:46 UTC

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21 jul 2026, 19:56 UTC

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20 jul 2026, 20:02 UTC

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.